The global health and economic value of COVID-19 vaccination.

Autor:	Sevilla JP; Data for Decisions, LLC, Waltham, Massachusetts, USA jsevilla@datafordecisions.net.; Harvard T H Chan School of Public Health, Boston, Massachusetts, USA., Burnes D; Data for Decisions, LLC, Waltham, Massachusetts, USA., Knee JS; Data for Decisions, LLC, Waltham, Massachusetts, USA., Di Fusco M; Pfizer Inc, New York, New York, USA., Kyaw MH; Pfizer Inc, New York, New York, USA., Yang J; Pfizer Inc, New York, New York, USA., Nguyen JL; Pfizer Inc, New York, New York, USA., Bloom DE; Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	BMJ global health [BMJ Glob Health] 2024 Sep 07; Vol. 9 (9). Date of Electronic Publication: 2024 Sep 07.
DOI:	10.1136/bmjgh-2024-015031
Abstrakt:	Introduction: The COVID-19 pandemic triggered one of the largest global health and economic crises in recent history. COVID-19 vaccination (CV) has been the central tool for global health and macroeconomic recovery, yet estimates of CV's global health and macroeconomic value remain scarce. Methods: We used regression analyses to measure the impact of CV on gross domestic product (GDP), infections and deaths. We combined regression estimates of vaccine-averted infections and deaths with estimates of quality-adjusted life years (QALY) losses, and direct and indirect costs, to estimate three broad value components: (i) QALY gains, (ii) direct and indirect costs averted and (iii) GDP impacts. The global value is the sum of components over 148 countries between January 2020 and December 2021 for CV generally and for Pfizer-BioNTech specifically. Results: CV's global value was US$5.2 (95% CI US$4.1 to US$6.2) trillion, with Pfizer-BioNTech's vaccines contributing over US$1.9 (95% CI US$1.5 to US$2.3) trillion. Varying key parameters results in values 10%-20% higher or lower than the base-case value. The largest value component was GDP impacts, followed by QALY gains, then direct and indirect costs averted. CV provided US$740 of value per dose, while Pfizer-BioNTech specifically provided >US$1600 per dose. We estimated conservative benefit-cost ratios of 13.9 and 30.8 for CV and Pfizer-BioNTech, respectively. Conclusions: We provide the first estimates of the broad value of CV incorporating GDP, QALY and direct and indirect cost impacts. Through December 2021, CV produced significant health and economic value, represented strong value for money and produced significant macroeconomic benefits that should be considered in vaccine evaluation. Competing Interests: Competing interests: JPS, DB and JSK are employees of Data for Decisions (DfD) and worked on this study in that capacity. JPS and DB have worked on other studies funded by grants from Pfizer Inc. to DfD. DEB is an external consultant to DfD and in that capacity has worked on this and other studies funded by grants from Pfizer Inc. to DfD. JPS and DEB in their personal capacities have received compensation from Pfizer Inc. for providing consulting services and for speaking and participating in meetings and advisory boards. MDF, MK, JLN and JY are employees of Pfizer Inc. and each held Pfizer stock or stock options at the time of the study. Pfizer Inc. employs MDF, MK, JLN and JY, but otherwise played no role in study design, data collection and analysis, decision to publish or preparation of the article. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu